Testing effectiveness (Phase 2)Ended earlyNCT01766336
What this trial is testing
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Who this might be right for
Alzheimer's Disease
OPKO Health, Inc. 296